Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences

Leukemia

Volumn 31, Issue 4, 2017, Pages 821-828

  Waanders, E ^a   Scheijen, B ^a   Jongmans, M C J ^a,b   Venselaar, H ^c   Van Reijmersdal, S V ^a   Van Dijk, A H A ^a   Pastorczak, A ^d   Weren, R D A ^a   Van Der Schoot, C E ^e   Van De Vorst, M ^a   Sonneveld, E ^f   Hoogerbrugge, N ^a   Van Der Velden, V H J ^g   Gruhn, B ^h   Hoogerbrugge, P M ⁱ   Van Dongen, J J M ^g   Geurts Van Kessel, A ^a   Van Leeuwen, F N ^a   Kuiper, R P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h JENA UNIVERSITY HOSPITAL   (Germany)

ⁱ Department of Radiation Oncology   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; GENOMIC DNA; IMMUNOGLOBULIN; JANUS KINASE; PROTEIN KINASE TYK2; STAT PROTEIN; T LYMPHOCYTE RECEPTOR; PROTEIN BINDING;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ARTICLE; AUTOPHOSPHORYLATION; CANCER PATIENT; CHILD; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; COMPUTER MODEL; COPY NUMBER VARIATION; FEMALE; GENE; GENE REARRANGEMENT; GENETIC SUSCEPTIBILITY; GENETIC TRANSFECTION; GERMLINE MUTATION; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; MULTIPLEX POLYMERASE CHAIN REACTION; PEDIATRICS; PROTEIN KINASE TYK2 GENE; PROTEIN STRUCTURE; WESTERN BLOTTING; WHOLE EXOME SEQUENCING; AMINO ACID SUBSTITUTION; CHEMISTRY; EXOME; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HIGH THROUGHPUT SEQUENCING; METABOLISM; MOLECULAR MODEL; PHOSPHORYLATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN CONFORMATION; PROTEIN DOMAIN; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; AMINO ACID SUBSTITUTION; EXOME; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MODELS, MOLECULAR; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; STAT TRANSCRIPTION FACTORS; TYK2 KINASE;

EID: 84996802211     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.277     Document Type: Article

References (60)

1. Walsh M, Wu G, Edmonson M, Gruber TA, Easton J, Yergeau D et al. Incidence of germline mutations in cancer-predisposition genes in children with hematologic malignancies: a report from the pediatric cancer genome project. Blood 2014; 124: 127-127
2. Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J et al. Germline mutations in predisposition genes in pediatric cancer. New Engl J Med 2015; 373: 2336-2346
3. Auer F, Ruschendorf F, Gombert M, Husemann P, Ginzel S, Izraeli S et al. Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547G4A. Leukemia 2014; 28: 1136-1138
4. Shah S, Schrader KA, Waanders E, Timms AE, Vijai J, Miething C et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet 2013; 45: 1226-1231
5. Zhang MY, Churpek JE, Keel SB, Walsh T, Lee MK, Loeb KR et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet 2015; 47: 180-185
6. Topka S, Vijai J, Walsh MF, Jacobs L, Maria A, Villano D et al. Germline ETV6 mutations confer susceptibility to acute lymphoblastic leukemia and thrombocytopenia. PLoS Genet 2015; 11: e1005262
7. Noetzli L, Lo RW, Lee-Sherick AB, Callaghan M, Noris P, Savoia A et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet 2015; 47: 535-538
8. Moriyama T, Metzger ML, Wu G, Nishii R, Qian M, Devidas M et al. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncol 2015; 16: 1659-1666
9. van der Velden VH, de Launaij D, de Vries JF, de Haas V, Sonneveld E, Voerman JS et al. New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric B-cell precursor acute lymphoblastic leukaemia. Br J Haematol 2016; 172: 769-781
10. Szczepanski T, van der Velden VH, Waanders E, Kuiper RP, Van Vlierberghe P, Gruhn B et al. Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. J Cin Oncol 2011; 29: 1643-1649
11. MacDonald JR, Ziman R, Yuen RK, Feuk L, Scherer SW. The Database of Genomic Variants: a curated collection of structural variation in the human genome. Nucleic Acids Res 2014; 42(Database issue): D986-D992
12. Franke B, Vasquez AA, Veltman JA, Brunner HG, Rijpkema M, Fernandez G. Genetic variation in CACNA1C, a gene associated with bipolar disorder, influences brainstem rather than gray matter volume in healthy individuals. Biol Psychiatry 2010; 68: 586-588
13. Venkatachalam R, Verwiel ET, Kamping EJ, Hoenselaar E, Gorgens H, Schackert HK et al. Identification of candidate predisposing copy number variants in familial and early-onset colorectal cancer patients. Int J Cancer 2011; 129: 1635-1642
14. van der Velden VH, van Dongen JJ. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. Methods Mol Biol 2009; 538: 115-150
15. Vissers LE, de Ligt J, Gilissen C, Janssen I, Steehouwer M, de Vries P et al. A de novo paradigm for mental retardation. Nat Genet 2010; 42: 1109-1112
16. de Ligt J, Willemsen MH, van Bon BW, Kleefstra T, Yntema HG, Kroes T et al. Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med 2012; 367: 1921-1929
17. Lek M, Karczewski K, Minikel E, Samocha K, Banks E, Fennell T et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016; 536: 285-291
18. Genome of The Netherlands Consortium. Whole-genome sequence variation, population structure and demographic history of the Dutch population. Nat Genet 2014; 46: 818-825
19. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R et al. A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-183
20. Lupardus PJ, Ultsch M, Wallweber H, Bir Kohli P, Johnson AR, Eigenbrot C. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc Natl Acad Sci USA 2014; 111: 8025-8030
21. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148
22. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468: 968-972
23. Van Vlierberghe P, Palomero T, Khiabanian H, Van der Meulen J, Castillo M, Van Roy N et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet 2010; 42: 338-342
24. Zuurbier L, Petricoin EF 3rd, Vuerhard MJ, Calvert V, Kooi C, Buijs-Gladdines JG et al. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. Haematologica 2012; 97: 1405-1413
25. Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009; 114: 647-650
26. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005; 42: 711-719
27. Greengard EG, Park JR. ALK-related neuroblastic tumor susceptibility. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH et al. (eds). GeneReviews (R): Seattle, WA, USA, 1993
28. George RE, Sanda T, Hanna M, Frohling S, Luther W 2nd, Zhang J et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008; 455: 975-978
29. Kuefer MU, Chinwalla V, Zeleznik-Le NJ, Behm FG, Naeve CW, Rakestraw KM et al. Characterization of the MLL partner gene AF15q14 involved in t(11;15)(q23;q14). Oncogene 2003; 22: 1418-1424
30. Yang JJ, Park TS, Lee ST, Seo JY, Oh SH, Cho EH et al. Molecular characterization and clinical impact of t(11;15)(q23;q14-15) MLL-CASC5 rearrangement. Haematologica 2014; 99: e11-e13
31. Hammaren HM, Ungureanu D, Grisouard J, Skoda RC, Hubbard SR, Silvennoinen O ATP. binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Proc Natl Acad Sci USA 2015; 112: 4642-4647
32. Murphy JM, Zhang Q, Young SN, Reese ML, Bailey FP, Eyers PA et al. A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties. Biochem J 2014; 457: 323-334
33. Alaggio R, Collini P, Randall RL, Barnette P, Million L, Coffin CM. Undifferentiated high-grade pleomorphic sarcomas in children: a clinicopathologic study of 10 cases and review of literature. Pediatr Dev Pathol 2010; 13: 209-217
34. Crescenzo R, Abate F, Lasorsa E, Tabbo F, Gaudiano M, Chiesa N et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 2015; 27: 516-532
35. Kalender Atak Z, De Keersmaecker K, Gianfelici V, Geerdens E, Vandepoel R, Pauwels D et al. High accuracy mutation detection in leukemia on a selected panel of cancer genes. PLoS One 2012; 7: e38463
36. Leich E, Weissbach S, Klein HU, Grieb T, Pischimarov J, Stuhmer T et al. Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion-and receptor tyrosine kinase signaling molecules. Blood Cancer J 2013; 3: e102
37. Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov 2013; 3: 564-577
38. Velusamy T, Kiel MJ, Sahasrabuddhe AA, Rolland D, Dixon CA, Bailey NG et al. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood 2014; 124: 3768-3771
39. Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012; 22: 153-166
40. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014; 371: 1005-1015
41. Harvey RC, Mullighan CG, Chen IM, Wharton W, Mikhail FM, Carroll AJ et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010; 115: 5312-5321
42. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009; 106: 9414-9418
43. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157-163
44. Zhang J, Mullighan CG, Harvey RC, Wu G, Chen X, Edmonson M et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011; 118: 3080-3087
45. Bellanger D, Jacquemin V, Chopin M, Pierron G, Bernard OA, Ghysdael J et al. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. Leukemia 2014; 28: 417-419
46. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061
47. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790
48. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397
49. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005; 76: 528-537
50. Wellcome Trust Case Control Consortium and Australo-Anglo-American Spondylitis Consortium, Burton PR, Clayton DG, Cardon LR, Craddock N et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007; 39: 1329-1337
51. Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006; 25: 745-755
52. Kilic SS, Hacimustafaoglu M, Boisson-Dupuis S, Kreins AY, Grant AV, Abel L et al. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J Pediatrics 2012; 160: 1055-1057
53. Ishizaki M, Akimoto T, Muromoto R, Yokoyama M, Ohshiro Y, Sekine Y et al. Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J Immunol 2011; 187: 181-189
54. Ishizaki M, Muromoto R, Akimoto T, Sekine Y, Kon S, Diwan M et al. Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int Immunol 2014; 26: 257-267
55. Stoiber D, Kovacic B, Schuster C, Schellack C, Karaghiosoff M, Kreibich R et al. TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest 2004; 114: 1650-1658
56. Magnusson S, Borg A, Kristoffersson U, Nilbert M, Wiebe T, Olsson H. Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes. Fam Cancer 2008; 7: 331-337
57. Brooks GA, Stopfer JE, Erlichman J, Davidson R, Nathanson KL, Domchek SM. Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic. Cancer Biol Ther 2006; 5: 1098-1102
58. Parsons DW, Roy A, Yang Y, Wang T, Scollon S, Bergstrom K et al. Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol 2016
59. Wu L, Sun T, Kobayashi K, Gao P, Griffin JD. Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol Cell Biol 2002; 22: 7688-7700
60. Bailis W, Pear WS. Notch and PI3K: how is the road traveled? Blood 2012; 120: 1349-1350